Geron (United States)

Recent papers from Geron (United States)

1. Overall survival and long-term outcomes from the randomized, double-blind, placebocontrolled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromesHaematologica · 2026
2. Updated protocol: IMPROVEMF, a phase 1b trial of imetelstat (IME)+ ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1/2 or high-risk (HR) myelofibrosis (MF).Journal of Clinical Oncology · 2026
3. Updated analysis of overall survival (OS) with imetelstat (IME) in relapsed/refractory (R/R) myelofibrosis (MF) versus real-world (RW) data, and assessment of RW treatment (tx) patterns.Journal of Clinical Oncology · 2026
4. Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge studyHaematologica · 2026
5. No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower‐Risk Myelodysplastic SyndromesClinical and Translational Science · 2025
6. Clinical outcomes and safety in patients with lower‐risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trialBritish Journal of Haematology · 2025
7. AMCP real-world evidence standards: Overcoming barriers to using real-world evidence in US payer decision-makingJournal of Managed Care & Specialty Pharmacy · 2025
8. Myeloid Cell Adhesion Molecule 1 (CADM1) Promotes Proinflammatory Signaling in Human Inflammatory Bowel DiseasesCellular and Molecular Gastroenterology and Hepatology · 2025
9. Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational AnalysisClinical and Translational Science · 2025
10. Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge studyLeukemia & lymphoma/Leukemia and lymphoma · 2024
11. Imetelstat, a novel, first‐in‐class telomerase inhibitor: Mechanism of action, clinical, and translational scienceClinical and Translational Science · 2024
12. Creating LGBTQIA+-Inclusive Health Care as a Supportive Care StrategyClinical journal of oncology nursing · 2024
13. Efficacy of imetelstat on red blood cell (RBC)-transfusion independence (TI) in the absence of platelet transfusions or myeloid growth factors in IMerge.Journal of Clinical Oncology · 2024
14. Population pharmacokinetics of imetelstat, a first‐in‐class oligonucleotide telomerase inhibitorCPT Pharmacometrics & Systems Pharmacology · 2024
15. CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs)Journal of the National Comprehensive Cancer Network · 2024
16. HSR24-159: Relationship Between Durable Transfusion Independence (TI) and Survival Outcomes in Patients (Pts) With Lower-Risk Myelodysplastic Syndrome (LR-MDS): An Analysis From US Health Insurance Claims DataJournal of the National Comprehensive Cancer Network · 2024
17. Screen or No Screen? Lessons Learnt from a Real-World Deployment Study of Using Voice Assistants With and Without Touchscreen for Older Adults2023
18. Extreme Niche Partitioning and Microbial Dark Matter in a Mauna Loa Lava TubeJournal of Geophysical Research Planets · 2023
19. Improving heart failure care and guideline-directed medical therapy through proactive remote patient monitoring-home telehealth and pharmacy integrationBMJ Open Quality · 2022
20. Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study designFuture Oncology · 2022